<DOC>
	<DOCNO>NCT01463956</DOCNO>
	<brief_summary>Evaluation efficacy triple therapy pegylated interferon , ribavirin , boceprevir patient genotype 1 chronic hepatitis C , treatment-naive , relapsed , non-responders cirrhosis await liver transplantation , MELD score less equal 18</brief_summary>
	<brief_title>Efficacy PegInterferon-Ribavirin-Boceprevir Therapy Patients Infected With G1 HCV With Cirrhosis , Awaiting Liver Transplantation</brief_title>
	<detailed_description>Evaluation sustain virological response define proportion patient undetectable hepatitis C virus RNA 24 week discontinuation therapy and/or liver transplantation patient genotype 1 , treatment-naive , relapsed , non-responders cirrhosis await liver transplantation , MELD score less equal 18</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Liver Cirrhosis , Experimental</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Adult 18 year old Chronic infection hepatitis C virus proven positive PCR 6 month Viral genotype 1 Cirrhosis await liver transplantation MELD score &lt; equal 18 With without hepatocellular carcinoma Naive antiviral C treatment Failure previous treatment . Failure define persistence detectable HCV RNA . The previous HCV failure treatment profile must able document accord follow terminology : Relapsing patient : HCV RNA undetectable end treatment , become detectable discontinuation treatment Breakthrough : increase viremia 1 log treatment Nonresponding patient partial response : HCV RNA detectable W24 without ever undetectable decrease HCV RNA â‰¥ 2 log W12 Nonresponding patient nul response : decrease HCV RNA &lt; 2 log W12 No need prior treatment washout Negative pregnancy test woman childbearing age Double method contraception men woman childbearing age entire duration treatment 6 month follow discontinuation Free , inform , write consent ( sign day preenrollment late exam require study ) Person enrol beneficiary social security/Universal Health Insurance Coverage Inclusion approve Decision Support Committee Previous HCV treatment boceprevir telaprevir Alcohol consumption &gt; 40 g/day Toxicomania constitute barrier start therapy accord opinion investigator . Patients include methadone buprenorphine replacement program may enrol MELD &gt; 18 Non control sepsis Platelets &lt; 50,000/mm3 Neutrophil granulocyte level &lt; 1000/mm3 Creatinine clearance &lt; 50 mL/min ( MDRD ) Hb &lt; 10 g/dL Uncontrolled psychiatric problem Contraindications boceprevir Contraindication interferon ribavirin Subject major complication cirrhosis HIV coinfection HBV coinfection ( unless treat effectively analogue , proven undetectable viremia least 12 month ) Other infectious disease underway Neoplastic disease hepatocellular carcinoma previous year , neoplastic disease prognosis le 3 year Treatment immunosuppressor ( include corticosteroid ) , antiviral study , except aciclovir Consumption St. John 's wort Associated treatment include molecule substance could interfere pharmacokinetic characteristic boceprevir History lactose allergy Person participate another study include exclusion period still underway preenrollment Socalled vulnerable population ( minor , people guardianship protection , private individual protection make legal administrative decision ) Pregnancy , breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Boceprevir</keyword>
	<keyword>HCV infection</keyword>
	<keyword>Antiviral therapy</keyword>
	<keyword>Liver transplantation</keyword>
</DOC>